Form 8-K - Current report:
SEC Accession No. 0001213900-26-048064
Filing Date
2026-04-27
Accepted
2026-04-27 16:58:16
Documents
15
Period of Report
2026-04-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0287728-8k_inmed.htm   iXBRL 8-K 34642
2 SABBY PREFERRED INVESTMENT OPTION AMENDING AGREEMEN ea028772801ex10-1.htm EX-10.1 11766
3 FORM OF WAINWRIGHT PREFERRED INVESTMENT OPTION AMENDING AGREEMENT ea028772801ex10-2.htm EX-10.2 13962
4 PRESS RELEASE ea028772801ex99-1.htm EX-99.1 12787
5 GRAPHIC ea028772801_ex99-1img1.jpg GRAPHIC 9690
  Complete submission text file 0001213900-26-048064.txt   267227

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE inm-20260421.xsd EX-101.SCH 3002
8 XBRL LABEL FILE inm-20260421_lab.xml EX-101.LAB 34239
9 XBRL PRESENTATION FILE inm-20260421_pre.xml EX-101.PRE 22351
20 EXTRACTED XBRL INSTANCE DOCUMENT ea0287728-8k_inmed_htm.xml XML 3461
Mailing Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8
Business Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 26901835
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)